Company Overview

IM Cannabis Corp. is a Canadian-based international cannabis company focused on the medical and adult-use cannabis markets, with operations historically centered in Israel, Germany, and Canada. The company operates through cultivation, distribution, retail, and branded cannabis product activities, serving both medical patients and recreational consumers where permitted by local regulations. Its revenue has primarily been driven by medical cannabis sales in Israel, wholesale distribution activities, and retail operations through controlled subsidiaries and licensed channels.

The company evolved through a series of mergers, acquisitions, and restructuring initiatives aimed at building a multinational cannabis platform. IM Cannabis traces its roots to Israeli cannabis operations and later expanded internationally through acquisitions including Trichome Financial Corp. and German distribution assets. The company has positioned itself around premium cannabis branding, international supply chain capabilities, and access to regulated medical cannabis markets, particularly Israel’s established medical cannabis framework and Germany’s pharmaceutical distribution environment.

Business Operations

IM Cannabis conducts operations through several principal business units and subsidiaries. Its activities have included cultivation, importation, distribution, logistics, and retail sales of cannabis products. Key operating entities have included IMC Holdings Ltd. in Israel, Adjupharm GmbH in Germany, and Canadian subsidiaries tied to cannabis retail and distribution activities. Revenue generation has historically come from medical cannabis sales, wholesale distribution agreements, retail cannabis stores, and branded product sales.

The company’s operations span both domestic and international markets. In Israel, IM Cannabis has participated in the regulated medical cannabis supply chain through sourcing, branding, and distribution relationships. In Germany, Adjupharm GmbH has operated as a pharmaceutical distributor importing and distributing medical cannabis products under European regulatory standards. The company has also maintained strategic sourcing relationships with cultivators and cannabis producers in multiple jurisdictions to support product availability and supply diversification. Public filings have indicated periodic restructuring efforts intended to reduce operating costs and streamline international operations.

Strategic Position & Investments

IM Cannabis has pursued a strategy focused on regulated medical cannabis markets with established patient frameworks and pharmaceutical oversight. The company has emphasized premium branded products, cross-border cannabis distribution, and leveraging Israel and Germany as core strategic markets. Growth initiatives disclosed in public filings have included expansion of medical cannabis product offerings, optimization of supply chain partnerships, and operational restructuring intended to improve liquidity and reduce expenses.

Major strategic transactions have included the acquisition of Trichome Financial Corp., which expanded the company’s financial and operational footprint in Canada, and the development of the Adjupharm GmbH platform in Germany. The company has also entered supply and distribution agreements with international cannabis producers to secure product access for European and Israeli markets. Public disclosures indicate ongoing evaluation of capital allocation priorities and operational efficiency measures amid broader volatility in the global cannabis sector.

Geographic Footprint

IM Cannabis has maintained a multinational operational presence with headquarters in Canada and significant activities in Israel and Germany. Israel has historically represented one of the company’s largest operating markets due to its established medical cannabis infrastructure and patient base. Germany has served as a strategic European market through pharmaceutical distribution operations and medical cannabis imports.

The company’s international footprint has included sourcing relationships and operational ties across North America, Europe, and the Middle East. Its business model has relied in part on international cannabis trade frameworks that permit regulated import and export activity for medical cannabis products. Public filings and investor materials have indicated continued focus on markets with federally regulated medical cannabis systems rather than fragmented regional recreational frameworks.

Leadership & Governance

IM Cannabis has operated under a publicly traded corporate governance structure with executive leadership overseeing international cannabis operations, capital markets activity, and regulatory compliance. Leadership strategy has emphasized international expansion within regulated medical cannabis markets, operational restructuring, and cost discipline in response to changing cannabis market conditions and capital availability.

Key executives and leadership figures identified in recent public disclosures include:

• Oren Shuster – Chief Executive Officer
• Nir Zohar – President
• Avi Shemesh – Director
• Marc Lustig – Chairman of the Board
• Oren Rosenfeld – Chief Financial Officer

Public company governance has included oversight through a board of directors and reporting obligations under Canadian securities regulations and U.S. market disclosure standards. Executive leadership commentary in corporate filings has consistently emphasized disciplined international growth, regulatory compliance, and strengthening positions in core medical cannabis jurisdictions.